logo
logo

Gro Biosciences Announces $25M Series A Financing Led By Leaps By Bayer And Redmile Group

Gro Biosciences Announces $25M Series A Financing Led By Leaps By Bayer And Redmile Group

11/03/21, 10:55 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgboston
Money raised
$25 million
Round Type
series a
GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of a Series A financing totaling $25 million co-led by Leaps by Bayer and Redmile Group. The financing was joined by lead seed investors Digitalis Ventures, Innovation Endeavors and others bringing the total investment to $31.2 million.

Company Info

Company
Gro Biosciences
Location
boston, massachusetts, united states
Additional Info
GRO Biosciences (“GRObio”) is leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. The Company is transforming treatments in diverse areas including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries. The Company’s NSAA therapeutics feature previously unattainable capabilities including unprecedented duration of action and precise regulation of the immune system. GRObio, co-founded by Dr. George Church of Harvard Medical School in 2016, is headquartered in Cambridge, MA. Find GRObio on LinkedIn, Twitter, Instagram, Facebook and the web at grobio.com.